Aardvark Therapeutics (AARD) vs Unicycive Therapeutics (UNCY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Unicycive Therapeutics (UNCY) has outperformed Aardvark Therapeutics (AARD) over the past year, losing 14.7% versus a loss of 72.5%. Unicycive Therapeutics is the larger company by market cap ($114.2 million vs $103.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AARD | UNCY |
|---|---|---|
| Share price | $4.72 | $4.17 |
| Market cap | $103.19M | $114.23M |
| 1-day change | +0.11% | +2.46% |
| YTD return | -64.11% | -29.46% |
| 1-year return | -72.50% | -14.68% |
| 5-year return | — | -85.06% |
| Forward P/E | — | 2.47 |
| EPS (TTM) | $-3.21 | $-1.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.06 | $8.74 |
| 52-week low | $3.35 | $3.93 |
| Distance from 52-week high | -72.35% | -52.29% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +135.63% | +581.06% |
| Average volume | 208.11K | 839.29K |
| Shares outstanding | 21.88M | 27.39M |
| Employees | 28 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- UNCY has outperformed AARD by 57.8 percentage points over the past year.
About Aardvark Therapeutics
AARD stock →Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
About Unicycive Therapeutics
UNCY stock →Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
AARD vs UNCY FAQ
Which is bigger, Aardvark Therapeutics or Unicycive Therapeutics?
Unicycive Therapeutics (UNCY) is larger, with a market capitalization of $114.23M compared with $103.19M for Aardvark Therapeutics (AARD).
Which stock has performed better over the past year, AARD or UNCY?
UNCY returned -14.68% over the past 12 months, compared with -72.50% for AARD (price return, excluding dividends). Past performance does not predict future results.
Are Aardvark Therapeutics and Unicycive Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.